ライフサイエンスコーパス: osteolytic

1 LNCaP bone tumors were both osteoblastic and osteolytic.

2 derately osteoblastic LM8 (P < 0.05) and the osteolytic 143B (P < 0.01) cell line-derived tumors.

3 that give rise to advanced bone cancer pain, osteolytic 2472 sarcoma cells or media were injected int

4 pain, we used an in vivo model where murine osteolytic 2472 sarcoma cells were injected and confined

5 The majority of the osteolytic (72; 93.5%) and mixed-pattern lesions (nine;

6 The 146 lesions were classified as osteolytic (77), osteoblastic (41), mixed-pattern (11),

7 NKL) with osteoprotegerin (OPG) prevents the osteolytic activity of CaP and its ability to establish

8 expression of target genes that mediate the osteolytic activity of metastatic breast cancer cells.

9 eoblastic activity, but had no effect on its osteolytic activity.

10 aled the mixed bone lesions, comprising both osteolytic and osteoblastic elements.

11 ese effects were enhanced in the presence of osteolytic and osteoblastic factors such as RANKL (recep

12 s can be useful tools in characterizing pure osteolytic and osteoblastic lesions induced by human pro

13 andardized uptake values [SUVs]) of 18FDG in osteolytic and osteoblastic metastases were compared.

14 pressing LNCaP cells (LNCaP-PDGF-D) revealed osteolytic and osteoblastic responses similar to those o

15 tably, the model revealed distinct phases of osteolytic and osteogenic activity, a critical role for

16 We review the biology of osteolytic and osteosclerotic lesions, with a focus on e

17 ce for close interplay between inflammatory, osteolytic and tumor cell-driven events in the bone-tumo

18 inally assess the formation of osteoblastic, osteolytic, and mixed lesions formed by human prostate c

19 ppears to be the centerpiece of inflammatory-osteolytic arthritis and direct inhibition of this trans

20 Interestingly, ATL cells overexpressed the osteolytic-associated genes-Wnt5a, PTHLH, and RANKL.

21 teum, similar to that found in patients with osteolytic bone cancer.

22 Osteolytic bone destruction and its complications, bone

23 The osteolytic bone destruction associated with breast cance

24 a tumor-bone co-culture system and enhances osteolytic bone destruction in mice, but also inhibits o

25 a support a model in which tumor cells cause osteolytic bone destruction independently of the RANK li

26 d with human metastatic bone disease such as osteolytic bone destruction.

27 al for the development of metastasis-related osteolytic bone destruction.

28 ould decrease PTHrP expression and therefore osteolytic bone destruction.

29 a key role in the pathogenesis of MM-related osteolytic bone disease (OBD).

30 factor, osteoprotegerin, were protected from osteolytic bone disease and developed fewer soft-tissue

31 masome-independent production of IL-1beta in osteolytic bone disease and identify PSTPIP2 as a negati

32 roid hormone-related peptide (PTHrP), namely osteolytic bone disease associated with breast cancer an

33 y multiple myeloma (MM) cells contributes to osteolytic bone disease by inhibiting the differentiatio

34 y play a critical role in the development of osteolytic bone disease in multiple myeloma and that tar

35 Il1r and Il1beta, but not Il1alpha, rescued osteolytic bone disease in mutant mice.

36 ized the osteoimmunological underpinnings of osteolytic bone disease in Pstpip2(cmo) mice.

37 Osteolytic bone disease is a major cause of morbidity in

38 del, treatment with NB-DNJ markedly improved osteolytic bone disease symptoms.

39 e marrow, elevated serum immunoglobulin, and osteolytic bone disease.

40 onment in myeloma counteracts development of osteolytic bone disease.

41 multiple myeloma progression and associated osteolytic bone disease.

42 ls in the bone marrow and the development of osteolytic bone disease.

43 ted with tumor growth within bone marrow and osteolytic bone disease.

44 can promote myeloma growth and survival and osteolytic bone disease.

45 oma (MM), particularly in the development of osteolytic bone disease.

46 nists for the treatment of MM and associated osteolytic bone disease.

47 on of GSLs in osteoclast (OC) activation and osteolytic bone diseases in malignancies such as the pla

48 identify increased numbers of osteoclasts in osteolytic bone diseases such as osteolytic bone metasta

49 new therapeutic approaches to combat various osteolytic bone diseases.

50 ie2 activity in vivo significantly inhibited osteolytic bone invasion and tumor growth in a mammary t

51 w function of Tie2 in osteoclastogenesis and osteolytic bone invasion of breast cancer.

52 The risk for osteolytic bone lesion complications in metastatic breas

53 f symptomatic MM is a well-demarcated, focal osteolytic bone lesion.

54 Multiple myeloma (MM) is characterized by osteolytic bone lesions (OBL) that arise as a consequenc

55 splacement of hematopoiesis and formation of osteolytic bone lesions also known as myeloma bone disea

56 major contributing factor to the increase in osteolytic bone lesions and hypercalcemia found in ATL p

57 read dissemination of tumor cells leading to osteolytic bone lesions and liver metastases, common sit

58 t increased IL-1 signaling can cause aseptic osteolytic bone lesions and that the absence of IL-10 si

59 acid phosphatase to confirm the presence of osteolytic bone lesions and the presence of osteoclasts,

60 andibular alveolar processes for presence of osteolytic bone lesions around causative teeth roots and

61 nt pathogenetic role in the establishment of osteolytic bone lesions in breast cancer.

62 day) significantly reduced the occurrence of osteolytic bone lesions in myeloma-bearing mice.

63 sk of skeletal complications associated with osteolytic bone lesions in patients with breast cancer a

64 r an effective therapeutic approach to treat osteolytic bone lesions in patients with myeloma.

65 Strong TGF-beta signaling in osteolytic bone lesions is suppressed directly by geneti

66 timyeloma therapy, regardless of presence of osteolytic bone lesions on conventional radiography.

67 Multiple myeloma (MM) is characterized by osteolytic bone lesions with uncoupled bone remodeling.

68 prevented myeloma-induced bone loss, reduced osteolytic bone lesions, and increased fracture resistan

69 cells may be important in the hypercalcemia, osteolytic bone lesions, neutrophilia, elevation of C-re

70 Specifically, osteolytic bone lesions, where bone is destroyed, lead t

71 Breast cancer (BCa) bone metastases cause osteolytic bone lesions, which result from the interacti

72 oclast formation, and radiologic evidence of osteolytic bone lesions.

73 E suppressed bone colonization and decreased osteolytic bone lesions.

74 t was expressed in two of three specimens of osteolytic bone metastases (P=0.0119).

75 develop radiographically detectable multiple osteolytic bone metastases and cachexia in this model.

76 e that Smad4 contributes to the formation of osteolytic bone metastases and is essential for the indu

77 u-RGD has the potential to effectively image osteolytic bone metastases and monitor the physiologic c

78 (RGDyK) ((64)Cu-RGD) as an imaging agent for osteolytic bone metastases and their associated inflamma

79 ed, inhibited the progression of established osteolytic bone metastases as assessed by radiographic a

80 mor inoculation prevented the development of osteolytic bone metastases compared with vehicle.

81 cer cells may be vital to the development of osteolytic bone metastases in patients with breast cance

82 s to bone, we used an in vivo model in which osteolytic bone metastases preferentially occur after in

83 usly developed hypercalcemia, high-frequency osteolytic bone metastases, and enhanced osteoclast acti

84 y promoting hypercalcemia, tumor growth, and osteolytic bone metastases, but it is not known how PTHr

85 east cancer cells, which consistently formed osteolytic bone metastases, induced osteosclerotic lesio

86 eature of our findings was the occurrence of osteolytic bone metastases, which are prominent in human

87 d that seven different mouse models of human osteolytic bone metastases-representing breast, lung and

88 THrP-neutralizing antibody greatly decreased osteolytic bone metastases.

89 tases, induced osteosclerotic lesions in the osteolytic bone metastases.

90 the use of bisphosphonates in patients with osteolytic bone metastases.

91 the use of bisphosphonates in patients with osteolytic bone metastases.

92 n women with stage IV breast cancer who have osteolytic bone metastases.

93 eoclasts in osteolytic bone diseases such as osteolytic bone metastasis and inflammatory osteolysis.

94 animal model of high-penetrance spontaneous osteolytic bone metastasis and underscore the critical r

95 EGF receptor (EGFR) inhibitors block osteolytic bone metastasis by targeting EGFR signaling i

96 into the left cardiac ventricle resulted in osteolytic bone metastasis in 74% of beta3+/+ mice by 14

97 rolling not only tumor angiogenesis but also osteolytic bone metastasis in breast cancer.

98 ious carcinomas such as breast cancer, where osteolytic bone metastasis is associated with increased

99 We further observed that osteolytic bone metastasis led to a decrease in HA nanoc

100 rget of NF-kappaB and found that it mediates osteolytic bone metastasis of breast cancer by stimulati

101 ppaB (NF-kappaB) plays a crucial role in the osteolytic bone metastasis of breast cancer by stimulati

102 to evaluate the mechanism of MMP13-dependent osteolytic bone metastasis revealed that MMP13-ASO treat

103 over a new and specific role of NF-kappaB in osteolytic bone metastasis through GM-CSF induction, sug

104 e inoculated with MDA-MB-231 cells developed osteolytic bone metastasis without hypercalcemia or incr

105 id hormone-related protein (PTHrP), enhanced osteolytic bone metastasis, and decreased survival.

106 al for the bone resorption characteristic of osteolytic bone metastasis.

107 ting tumor-stromal interactions that promote osteolytic bone metastasis.

108 ncer and implicate Rho-TGF-beta crosstalk in osteolytic bone metastasis.

109 ivo inhibits osteoclast activity and reduces osteolytic bone metastasis.

110 wed that they have the ability to reduce the osteolytic bone resorption associated with multiple myel

111 g DKK1 activity in myelomatous bones reduces osteolytic bone resorption, increases bone formation, an

112 Wu et al. identify MAOA as a key mediator of osteolytic bone responses that involve complex paracrine

113 or cells regulates processes associated with osteolytic bone tumor burden, we stably infected the bon

114 a unique expression signature that promotes osteolytic breast cancer bone metastasis and that inhibi

115 ior to bone scintigraphy in the detection of osteolytic breast cancer metastases, which led to a poor

116 in immune-compromised animals bearing human osteolytic cancers.

117 Using a mouse model that mimics osteolytic changes associated with breast cancer-induced

118 CT revealed osteolytic changes in 41 (31%) and osteoblastic changes

119 PTHLH), leading to osteoclast maturation for osteolytic colonization.

120 ls perpetuate the inflammatory response, the osteolytic component of this disease is a direct result

121 may block TGF-beta propagation of a vicious osteolytic cycle in this MDA-MB-231 model of bone metast

122 sequently, pDC and CD4(+) T cells, producing osteolytic cytokines, increased with tumor burden, causi

123 duce a profound decrease in tumor burden and osteolytic damage in the murine 5TGM1 model of MM bone d

124 1beta expression precedes the development of osteolytic damage in young Pstpip2(cmo) mice, and geneti

125 Conventional radiographs showed a small osteolytic defect in the anterior cortex of the midtibia

126 round also demonstrated striking spontaneous osteolytic destruction of distal phalanges.

127 Survival was lower in patients with osteolytic disease compared with the remainder (P=.01).

128 myeloma cells also reduced the formation of osteolytic disease in vivo after intratibial engraftment

129 mechanism by which Runx2 contributes to the osteolytic disease induced by MDA-MB-231 cells, we inves

130 ion of factors involved in the generation of osteolytic disease remain elusive.

131 ivin A levels were found in MM patients with osteolytic disease.

132 one-resorbing factors (PTHrP, IL8) promoting osteolytic disease.

133 2 short hairpin RNA inhibition prevented the osteolytic disease.

134 s and the bone microenvironment that lead to osteolytic disease.

135 Osteolytic diseases, including rheumatoid arthritis, ost

136 heumatoid arthritis, osteoporosis, and other osteolytic disorders.

137 rP, consistent with its previously described osteolytic effects in metastatic bone disease, can also

138 To determine whether the osteolytic factor parathyroid hormone-related protein (P

139 ich in turn increases secretion of important osteolytic factors such as parathyroid hormone-related p

140 one-invasive oral SCC (OSCC) derived from an osteolytic feline OSCC.

141 C3H mice were injected with osteolytic fibrosarcoma cells in and around the calcaneu

142 Unilateral injection of osteolytic fibrosarcoma cells into and around the calcan

143 When tumors formed after injection of osteolytic fibrosarcoma cells into the calcaneus bone of

144 se-directed processing of PTHrP disables the osteolytic functions of the mature hormone to promote os

145 x polymicrobial biofilm-induced inflammatory osteolytic gingival infection that results in orofacial

146 his study, we report that DKK-1 knockdown in osteolytic human PCa cells unexpectedly delays the devel

147 anism for modulating osteoclast signaling in osteolytic inflammatory disease.

148 Therapies to reverse tissue damage from osteolytic inflammatory diseases are limited by the inab

149 eering approach for the treatment of chronic osteolytic inflammatory diseases.

150 In a PC-3M-luc cell-induced osteolytic intraosseous model of prostate cancer, these

151 ue involvement, presence of an abscess or an osteolytic lesion around causative tooth.

152 mechanisms of inhibiting myeloma growth and osteolytic lesion development.

153 r interactions governing the early events of osteolytic lesion formation are currently unclear.

154 Surprisingly, osteolytic lesion formation was greatest in animals lack

155 tumours or systemic delivery of LOX leads to osteolytic lesion formation whereas silencing or inhibit

156 issemination in the bone marrow and enhanced osteolytic lesion formation, irrespective of HIF-1 Conve

157 er cells in the bone marrow and tumor-driven osteolytic lesion formation.

158 the progression of soft tissue necrosis and osteolytic lesion formation.

159 tion of LOX activity abrogates tumour-driven osteolytic lesion formation.

160 Infection of the dental pulp leads to an osteolytic lesion that results from a polymicrobial infe

161 ved to be central to the pathogenesis of the osteolytic lesion, the mechanisms by which this bacteria

162 ctures (45 [5%] vs 66 [7%]; p=0.04), and new osteolytic lesions (46 [5%] vs 95 [10%]; p<0.0001).

163 After treatment, 58 osteolytic lesions (80.5%) became [(18)F]FDG negative an

164 es that produce osteoblastic (MDA PCa 2b) or osteolytic lesions (PC-3).

165 CCR1 activation leads to the formation of osteolytic lesions and facilitates tumor growth.

166 toma cells recruited osteoclasts to generate osteolytic lesions and invade the bone matrix.

167 use model of bone metastasis, A77636 reduced osteolytic lesions and prevented mechanical weakening of

168 progeria-like disease phenotypes, including osteolytic lesions and rib fractures, osteoporosis, slow

169 Osteolytic lesions are a painful consequence of metastas

170 s that these compounds reduce PTHrP-mediated osteolytic lesions associated with metastatic human brea

171 , our findings suggest a novel mechanism for osteolytic lesions caused by cancer cells metastasizing

172 treatment completely prevented radiographic osteolytic lesions caused by human MDA-MB-231 breast can

173 l analysis at weekly intervals revealed that osteolytic lesions developed in the control tibias by 2

174 Anti-Wnt5a therapy may prevent or reduce osteolytic lesions found in ATL patients and improve the

175 Multiple myeloma is incurable once osteolytic lesions have seeded at skeletal sites, but fa

176 s may correlate with a propensity to develop osteolytic lesions in arthritis.

177 pose tissue, micrognathia, osteoporosis, and osteolytic lesions in bone.

178 reast cancer cells can prevent production of osteolytic lesions in bone.

179 lopecia, micrognathia, dental abnormalities, osteolytic lesions in bones, and osteoporosis, which are

180 at MMP-13 is critical for the development of osteolytic lesions in MM and that targeting the MMP-13 p

181 activity of osteoblasts (OBs) contributes to osteolytic lesions in multiple myeloma (MM).

182 very effective in limiting the formation of osteolytic lesions in PC-3 implanted tibias by inhibitin

183 Osteolytic lesions in the ribs led to spontaneous bone f

184 on of DKK1 by MM cells likely contributes to osteolytic lesions in this disease by inhibiting Wnt sig

185 n several human cancer cell lines that cause osteolytic lesions in vivo and produce PTHrP (MDA-MB-231

186 ort that human neuroblastoma cells that form osteolytic lesions in vivo do not produce osteoclast-act

187 tumor cells abolishes their ability to form osteolytic lesions in vivo.

188 n osteoblastic reaction in vitro and induced osteolytic lesions in vivo.

189 bone scans have sensitivity limitations for osteolytic lesions manifested in MM.

190 veloped hypercalcemia and significantly more osteolytic lesions than mice bearing CHO/EV tumors, with

191 a cells in the bone marrow induces localized osteolytic lesions that rarely heal due to increased bon

192 Total area of osteolytic lesions was significantly lower in mice treat

193 ith established bone metastases, the size of osteolytic lesions was significantly reduced after 4 wee

194 bone marrow plasma from femurs affected with osteolytic lesions were increased 2.5-fold over correspo

195 Microscopic osteolytic lesions were observed adjacent to plasma cell

196 osteolysis in mice receiving control cells, osteolytic lesions were significantly reduced following

197 Osteolytic lesions were successfully quantified using sm

198 metastasis produced detectable, progressive osteolytic lesions within 3 weeks of intracardiac inject

199 those cells with increased IGF-IR form both osteolytic lesions within the tibiae and secondary tumor

200 evented splenomegaly, limited development of osteolytic lesions, and concomitantly reduced tumor grow

201 turn a suppressor of osteoclastic activity, osteolytic lesions, and disease burden in a preclinical

202 correlated with markers of bone resorption, osteolytic lesions, and markers of disease activity.

203 r survival, a smaller tumor burden, and less osteolytic lesions, as compared with mice bearing contro

204 C4-2B's ability to induce mixed osteoblastic/osteolytic lesions, C4-2B cells were stably transfected

205 tumor primarily metastasizes to bone to form osteolytic lesions, causing severe pain and pathological

206 In cancer-induced osteolytic lesions, cleavage of receptor activator of nu

207 geting osteoclasts, which are upregulated in osteolytic lesions, may facilitate earlier follow-up in

208 acquired immune response could contribute to osteolytic lesions, we injected the periodontal pathogen

209 The osteolytic lesions, which develop usually in the long bo

210 frequently metastasize to bone, resulting in osteolytic lesions, yet the underlying mechanisms are po

211 and decrease the progression of established osteolytic lesions.

212 n myeloma cells inhibited the development of osteolytic lesions.

213 mall group of Tax(+) animals presenting with osteolytic lesions.

214 nificantly prevented the formation of severe osteolytic lesions.

215 ant in the resulting suppression of skeletal osteolytic lesions.

216 essential for the formation of premetastatic osteolytic lesions.

217 cell line, C4-2B, induces mixed osteoblastic/osteolytic lesions.

218 te, significantly delayed the progression of osteolytic lesions.

219 alyses to identify molecular determinants of osteolytic lesions.

220 ue associated with progressive periarticular osteolytic lesions.

221 insipidus, bilateral ear discharge, and new osteolytic lesions.

222 with metastatic breast cancer who have known osteolytic lesions.

223 ne among those increased in MM patients with osteolytic lesions.

224 and B-symptoms and was found to have diffuse osteolytic lesions.

225 ssion, radiation or surgery to bone, and new osteolytic lesions.

226 ecrete osteoclastogenic factors that promote osteolytic lesions; however, the identity of these facto

227 MMP-7 and MMP-9 null mice were injected with osteolytic luciferase-tagged mammary tumor cell lines.

228 Ewing sarcoma, an osteolytic malignancy that mainly affects children and y

229 in level is elevated in multiple myeloma, an osteolytic malignancy, where it might serve as predictiv

230 wed a dramatically impaired capacity to form osteolytic metastases and induce cachexia.

231 n tyrosine phosphorylation induced 74% fewer osteolytic metastases as compared with the control group

232 Breast cancer commonly causes osteolytic metastases in bone, a process that is depende

233 one US and 12 European patients with painful osteolytic metastases involving bone were treated with i

234 RF ablation of painful osteolytic metastases is safe, and the relief of pain is

235 RFA of painful osteolytic metastases provides significant pain relief f

236 sms responsible for osteoclast activation in osteolytic metastases should lead to development of nove

237 carcinoma (RCC) patients often present with osteolytic metastases, we aimed to investigate serum scl

238 environment, leading to the establishment of osteolytic metastases.

239 ders such as osteoporosis and contributes to osteolytic metastases.

240 treatment of hypercalcemia of malignancy and osteolytic metastases.

241 ignificantly reduces skeletal morbidity from osteolytic metastases.

242 rapeutic targets to block progression toward osteolytic metastases.

243 studied in detail using an in vivo model of osteolytic metastases.

244 ents with carcinoma of the gall bladder with osteolytic metastasis (stage 4).

245 ths, 12 adult patients with a single painful osteolytic metastasis in whom radiation therapy or chemo

246 mportant regulator of TGF-beta responses and osteolytic metastasis of breast cancer cells.

247 is recommended in women with pain caused by osteolytic metastasis to relieve pain when used concurre

248 their role in tumor-bone interaction during osteolytic metastasis.

249 iation is crucial for improving treatment of osteolytic metastasis.

250 MGUS and suggest that cytokines elevated in osteolytic myeloma also may be associated with bone loss

251 one lesions in cervical cancer seem to be of osteolytic nature.

252 acilitate earlier follow-up in patients with osteolytic or mixed bone metastases.

253 Biofilm-induced inflammatory osteolytic oral infections, such as periodontitis and pe

254 es is problematic because the lesions can be osteolytic, osteoblastic, or mixed, and imaging modaliti

255 pletely prevented the establishment of mixed osteolytic/osteoblastic tibial tumors, as were observed

256 masked Wnt-mediated osteoblastic activity in osteolytic PC-3 cells, the cells were stably transfected

257 ted tumor formation in the bone, both in the osteolytic PC3 and osteoblastic/osteoclastic mixed C4-2B

258 nol-soluble modulins as aureolysin-degraded, osteolytic peptides that trigger osteoblast cell death a

259 differentiation in an otherwise predominant osteolytic phenomenon.

260 lls for bone and their tendency to induce an osteolytic phenotype are a result of interactions betwee

261 implicated in causing erosive arthritis, the osteolytic phenotypes of multiple myeloma and metastatic

262 ression was higher in cell lines with higher osteolytic potential in vivo.

263 These mutations block the invasive and osteolytic properties of MDA-MB-231 breast cancer cells

264 Overexpression of p45-sErbB3 in the osteolytic prostate cancer cell line PC-3 converted its

265 lization (osteopenia) is coupled to enhanced osteolytic resorption in En1 mutants.

266 bone phenotype, we also observed an enhanced osteolytic response following RANKL injection over the c

267 Fbn2(-/-) mice display a greater than normal osteolytic response to locally implanted lipopolysacchar

268 OC precursors, altering bone homeostasis and osteolytic responses.

269 immune and skeletal systems and suggests an osteolytic role of IL-12 in pathogenesis of periodontal

270 y-one days after intramedullary injection of osteolytic sarcoma cells into the femur, there was exten

271 Osteolytic sarcoma cells were implanted into the medulla

272 Higher SUVs were observed for osteolytic than osteoblastic disease (mean, 6.77 and 0.9

273 may provide a new molecular target for anti-osteolytic therapy.

274 genes may be relevant therapeutic targets in osteolytic tumor burden.

275 In vitro analyses revealed that osteolytic tumor cells lack expression of the Hh recepto

276 mor (GCT) of bone is a histologically benign osteolytic tumor featuring prominent osteoclast-like gia

277 ncer pain, the hyperalgesia that occurs with osteolytic tumor growth is associated with the sensitiza

278 ilarly resistant to bone loss resulting from osteolytic tumor growth.

279 ased OC activity on tumor growth in 2 murine osteolytic tumor models.

280 tivity converted the C4-2B cells to a highly osteolytic tumor.

281 The osteolytic tumors in the 143B model showed the highest u

282 g Tax (Tax(+)), which spontaneously develops osteolytic tumors throughout the vertebrae and hind limb

283 could effectively target metastasis to bone, osteolytic tumors, and soft tissue tumors.

284 is a very rare, aggressive, and progressive osteolytic tumour for which no standard medicinal treatm

285 hoplasty was efficacious in the treatment of osteolytic vertebral compression fractures resulting fro

286 efficacy of kyphoplasty in the treatment of osteolytic vertebral compression fractures resulting fro

287 rocedures were performed in 18 patients with osteolytic vertebral compression fractures resulting fro

288 PC3 and DU145 bone tumors were primarily osteolytic, whereas LNCaP bone tumors were both osteobla